At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 16 enrolled
Drug / intervention
mitoxantrone + etoposide + gemtuzumab ozogamicindrug
Likely dose
mitoxantrone + etoposide + gemtuzumab ozogamicin 10 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy
In Brief
A Phase 2 clinical trial evaluating mitoxantrone + etoposide + gemtuzumab ozogamicin for Acute Myeloid Leukemia. Completed, enrolled 16 participants across 1 site.
Detailed Summary
This study is an open-label, single arm phase II study which will examine the efficacy and toxicity of the combination therapy of GO, mitoxantrone and etoposide in patients who did not respond to first line induction therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Myeloid Leukemia
CountriesUnited States
CollaboratorsPfizer
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedFeb 2019
Enrollment StartFeb 2019
Primary CompletionFeb 2023
Study CompletionDec 2024
TodayJul 2026
First PostedFeb 15, 2019
Enrollment StartFeb 28, 2019
Primary CompletionFeb 2, 2023
Study CompletionDec 22, 2024
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 7.4 years ago
Interventions
mitoxantrone + etoposide + gemtuzumab ozogamicindrug
10 mg/m2 mitoxantrone days 1-5 + 100mg/m2 etoposide days 1-5 + 3mg/m2 gemtuzumab ozogamicin on day 6.